Earlier this month Only Medics, part of the Clinical Professionals Group, held their annual Physician2Pharma recruitment event for NHS medics looking to transition into the pharmaceutical industry. The event was invite only and attended by 40 people comprising of hand picked GMC registered physicians looking to make the transition from the NHS into the pharmaceutical
AstraZeneca have confirmed that they remain confident of generating annual sales of over $45 billion by 2023. The increase is expected as a result of accelerating growth momentum from both AstraZeneca’s existing products and those currently awaiting market approval. Five current growth platforms (diabetes, Brilinta, respiratory, Emerging Markets and Japan) currently account for over half
AstraZeneca has announced that they are acquiring tissue sample specialist, Definiens, increasing their oncology efforts. AstraZeneca’s MedImmune unit is paying an initial $150 million, followed by additional predetermined milestone payments, to acquire Definiens. AstraZeneca noted that Definiens has “pioneered a world-leading imaging and data analysis technology, known as Tissue Phenomics, which dramatically improves the identification
Bristol-Myers Squibb have announced positive third quarter results for 2014, beating earlier forecasts after stronger-than-expected revenues for the period. The biopharmaceutical company posted earnings on Friday of $721 million, or $0.43 a share, an increase from earnings of $692 million, or $0.42 per share, in Q3 of 2013. Once adjusted for special items, Bristol-Myers Squibb’s
A new initiative being led by the Medical Research Council (MRC) has been announced today involving more than £230 million being invested in a range of “revolutionary technologies” to identify the causes of diseases, such as cancer and dementia. The Clinical Research Infrastructure Initiative was announced by Chancellor George Osborne who commented that the funding
Roche has announced positive Q3 results for 2014, with pharmaceutical sales increasing by 4% in the third quarter to 9.13bn francs, while their diagnostics division grew by 7% to 2.65bn francs. The results were boosted by increased sales of Roche’s new breast cancer drugs, Perjeta and Kadcyla. Sales of Perjeta more than tripled to reach
New forecasts published by Decision Resources show an expected increase in the sales of medicines to treat chronic heart failure. The forecasts show growth from around $2.9 billion in 2013 to an expected $8.9 billion in 2023. Growth in seven main markets (US, UK, France, Germany, Italy, Spain and Japan) will be driven mainly by
Merck KGaA have today announced a new partnership with the Institute of Cancer Research (ICR) and the Wellcome Trust to develop cancer treatments. Merck KGaA’s Merck Serono unit will work with the UK organisations to identify inhibitors of tankyrase, an enzyme of the poly (ADP-ribose) polymerase (PARP) enzyme family. Specifically, the Institute of Cancer Research
Bayer have announced additional details on the future of their pharmaceutical research and development business following the announcement earlier this week that they will be concentrating on their healthcare and crop science businesses going forward. The announcement confirmed Bayer plans to float their material science division on the stock market and focus on life sciences,
A new report published by the Alzheimer’s Society has found that the cost of dementia in the UK has now surpassed £26 billion a year. The review by the London School of Economics and King’s College London, of dementia across the UK, found that the bulk of the costs associated with dementia are “unfairly” shouldered
